期刊文献+

唑来膦酸治疗恶性肿瘤骨转移性疼痛62例临床分析 被引量:2

Observation of Zoledronic Acid in the treatment of bone metastasis pain caused by malignant tumors
下载PDF
导出
摘要 目的:观察唑来膦酸治疗恶性肿瘤骨转移性疼痛的止痛效果与不良反应。方法:62例恶性肿瘤骨转移性疼痛患者给予唑来膦酸注射液4 mg,用100 ml生理盐水稀释后静脉滴注,每4周1次,连用2次。结果:临床骨转移性止痛效果显示,显效18例,有效32例,无效12例,总有效率为83.33%(50/62)。主要不良反应为恶心、呕吐、发热、转氨酶升高及低血钙,给予对症支持治疗后症状均可逆转。结论:唑来膦酸治疗恶性肿瘤骨转移性疼痛效果明显,不良反应可耐受。 Objective: To investigate the effect and adverse effect of Zoledronic Acid in the treatment of bone metastasis pain of malignant tumors.Methods: 62 patients with bone metastasis pain were treated with 4 mg Zoledronic Acid Injection diluted with 100 ml physiologic saline by intravenous drip infusion per 4 weeks.Two cycles of Zoledronic Acid were used before the response could be evaluated.Results: The effect of pain relieving by Zoledronic Acid showed that,18 cases were excellent,32 cases were effective,12 cases were invalid,and the total effective rate was 83.33%(50/62).The main adverse effects were upset of digestive tract,fever,high aminopherase and low calcium in blood,all could be removed by giving supportive treatments.Conclusion: The effect of malignant bone metastasis pain treated with Zoledronic Acid Injection is obvious and adverse effects are tolerant.
作者 李观荣
出处 《中国医药导报》 CAS 2010年第35期123-124,共2页 China Medical Herald
关键词 唑来膦酸 恶性肿瘤 骨转移性疼痛 不良反应 Zoledronic Acid Malignant tumor Bone metastasis pain Adverse effect
  • 相关文献

参考文献9

二级参考文献69

  • 1李钧,张楠,孔凡英,孙玉萍.唑来膦酸治疗恶性肿瘤骨转移研究进展[J].癌症进展,2005,3(5):486-489. 被引量:11
  • 2李同度 张元泽.癌症疼痛的处理[A]..肿瘤学(下册)[C].天津:天津科学技术出版社,1996.2725-2737.
  • 3[3]Kopnin,Stromskaya TP,Kondratov RV,et al.Influence of exogenous ras and p53 on P-glycoprotein function in immortalized rodent fibroblasts.Oncol Res,1995,7 (6):299
  • 4[4]Rosen LS,Gordon D,Tchekmedyian S,et al.Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors:A phaseⅢ,double-blind,randomized trial The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.J Clin Oncol,2003,15,21 (16):3150
  • 5[6]Wellington K,Goa KL.Zoledronic acid:a review of its use in the management of bone metastases and hypercalcaemia of malignancy.Drugs,2003,63 (4):417
  • 6[7]Saad F,Gleason DM,Murray R,et al.A randomized,placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.J Natl Cancer Inst,2002,94 (19):1458
  • 7[8]Rosen LS.Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors.Semin Oncol,2002,29 (6):s28
  • 8[1]Bukowski JF,Dascher CC,Das H.Alternative bisphosphonate targets and mechanisms of action.Biochem Biophys Res Commun,2005,328:746
  • 9[2]Ferretti G,Fabi A,Carlini P,et al.Zoledronic -acidinduced circulating level modifications of angiogenic factors,metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients.Oncology,2005,69:35
  • 10[3]Clézardin P,Ebetino FH,Fournier PG.Bisphosphonates and cancer-induced bone disease:Beyond their antiresorptive activity.Cancer Res,2005,65:4971

共引文献54

同被引文献7

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部